H.C. Wainwright raised the firm’s price target on Larimar Therapeutics (LRMR) to $16 from $15 and keeps a Buy rating on the shares following the Q4 report. The firm says a submission for Nomlabofusp for accelerated approval is expected by the end of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks